ADC Therapeutics SA (ADCT) Earnings Date & Reports

Key Takeaways

• ADC Therapeutics (ADCT) reported third quarter 2026 total revenue of $21.72 million, beating the consensus estimate of roughly $18.7 million.
• Net product revenue from its lead therapy ZYNLONTA reached about $21.0 million, up from $15.8 million in the same period a year earlier.
• The company posted a net loss of $0.16 per share, narrower than the roughly $0.21 loss analysts had expected, and an adjusted (non-GAAP) loss of just $0.06 per share.
• Total operating expenses fell 24% year over year, reflecting disciplined cost management and lower research and development spending.
• Cash and cash equivalents stood at $189.2 million, which management says supports an expected runway into 2029.
• For additional detail, you can review Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• To discover AI-driven market opportunities across thousands of stocks and ETFs, explore Trending AI Robots.

Earnings Context and Why It Matters

ADC Therapeutics is a commercial-stage biotech focused on antibody drug conjugates (ADCs), a class of targeted cancer therapies that link an antibody to a cancer-killing payload. Its lead product, ZYNLONTA, is approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of therapy. The third quarter report matters because it shows whether ZYNLONTA sales can grow while the company prepares pivotal clinical readouts aimed at expanding into earlier treatment lines and larger patient populations. With a shrinking cash balance and rising development costs, investors also watch expense discipline and the cash runway closely. The results confirm a company executing on commercial stability while awaiting catalysts that could reshape its long-term revenue trajectory.

Reported Results

For the quarter ended September 30, 2026, ADC Therapeutics reported total revenue of $21.72 million, up from $16.43 million a year earlier and above the consensus estimate of approximately $18.7 million. ZYNLONTA net product revenue was about $21.0 million, compared with $15.8 million in the prior-year period, driven primarily by higher sales volume. License and royalty revenue contributed $0.71 million.

The company reported a net loss of $25.3 million, or $0.16 per share, versus a net loss of $41.0 million, or $0.30 per share, in the third quarter of 2025. On a non-GAAP (adjusted) basis, the net loss was $8.8 million, or $0.06 per share, compared with $25.5 million, or $0.19 per share, a year earlier. Both figures beat analyst expectations. Total operating expenses declined 24% year over year to $36.1 million, with adjusted operating expenses down 29%, driven mainly by lower research and development spending. As of September 30, 2026, cash and cash equivalents were $189.2 million, down from $261.3 million at the end of 2025, with management guiding to a runway into 2029.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following ADC Therapeutics and similar names, it offers a structured way to surface new candidates and monitor shifting conditions.

Market Reaction and Investor Sentiment

Investor sentiment heading into the report had been improving, with ADCT shares up more than 50% over the trailing three months, though the stock remains sharply lower over the past year. The earnings beat on both revenue and the bottom line reinforces a narrative of stabilizing ZYNLONTA sales and tighter cost control. Still, the market's longer-term focus remains on clinical catalysts rather than a single quarter's results. Sentiment is likely to stay tied to data readouts from the LOTIS-7 combination study, potential regulatory progress in Japan, and presentations at the American Society of Hematology (ASH) annual meeting, where management has indicated multiple abstracts have been accepted.

Forward Outlook and Key Factors to Monitor

The most important upcoming catalyst for ADC Therapeutics is clinical data. Management has highlighted multiple abstracts accepted for presentation at ASH, including full results from the LOTIS-7 study, which evaluates ZYNLONTA in combination with another agent in B-cell malignancies. These data could support expanded use of ZYNLONTA and strengthen the company's growth case.

Investors should also watch regulatory and commercial milestones in Japan, where a potential approval would open a new geography for the product. On the financial side, the key monitor is whether expense discipline continues while the company funds late-stage development. Lower research and development spending has narrowed losses, but sustaining that trend without delaying important trials will be essential.

Finally, the balance sheet remains a focal point. With $189.2 million in cash and a stated runway into 2029, the company has reduced near-term financing risk, but continued cash burn and the timing of clinical milestones will shape how comfortable investors are with that cushion. As ZYNLONTA sales growth and data readouts unfold, the market will look for evidence that the company can convert pipeline progress into a meaningfully larger commercial opportunity.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations